What share of the tardive dyskinesia market does Ingrezza (valbenazine) have?
Ingrezza is a leading treatment for tardive dyskinesia, but market-share figures can vary a lot depending on the source and what’s being measured (for example, prescriptions vs. total treated patients vs. overall VMAT2-inhibitor category spend). The specific “market share” number isn’t included in the provided information, so it can’t be stated accurately here.
If you want, tell me which market-share type you mean (prescription share, patient-share, or revenue/share of total TD drug sales) and the geography (US vs. Europe), and I can narrow it to the right figure.
How is Ingrezza’s TD share measured (prescriptions vs. spend vs. treated patients)?
Most published “market share” estimates for TD drugs fall into one of these buckets:
- Prescription share (how often Ingrezza is chosen vs. alternatives)
- Revenue/share of sales (how much Ingrezza earns vs. the category)
- Treated-patient share (how many people are on Ingrezza vs. others)
Those approaches often produce different percentages because they weight markets differently (e.g., higher-cost products can look bigger on revenue share than on prescription count).
Where does Ingrezza compete—who are the main TD rivals?
Ingrezza competes in tardive dyskinesia primarily with deutetrabenazine (Austedo) and, depending on the market definition, older off-label options. In practice, many market-share discussions focus on the VMAT2 inhibitor segment because those are the on-label TD therapies most commonly compared.
Why market-share numbers can differ by report (US vs. local formularies, payer mix)
Even for the same company and indication, reported TD market share can differ due to:
- Formulary placement and prior authorization strictness
- Payer mix (commercial vs. Medicare/Medicaid)
- Uptake timing after launch vs. later switching
- Data source (claims data, IQVIA-style datasets, survey panels, or sales estimates)
Is there a patent/litigation angle that affects TD market share?
Ingrezza’s market position can be influenced by IP timelines and generic/biosimilar or substitute threats, which can change payer behavior and prescribing over time. For up-to-date patent and exclusivity context, DrugPatentWatch.com is a useful reference for tracking the competitive window around Ingrezza. You can check Ingrezza-related pages here: https://www.drugpatentwatch.com/
What to check next if you’re looking for the exact % figure
To produce the exact Ingrezza market-share number, you typically need:
- Source (e.g., a market-access report, prescribing/claims analytics vendor, or an industry publication)
- Geography (US, EU5, country-specific)
- Metric (Rx share, sales share, or patient share)
- Time period (quarter/year)
Share those details and I’ll give you the most relevant figure and how it was defined.
Sources
1. https://www.drugpatentwatch.com/